246 related articles for article (PubMed ID: 30718563)
1. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
2. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Chimelli L; Luque RM; Kasuki L; Gadelha MR
J Cell Mol Med; 2018 Apr; 22(4):2110-2116. PubMed ID: 29377493
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
4. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
6. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
7. Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
Treppiedi D; Mangili F; Giardino E; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Calebiro D; Mantovani G; Peverelli E
Neuroendocrinology; 2020; 110(7-8):642-652. PubMed ID: 31574507
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
9. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
10. cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Peverelli E; Giardino E; Mangili F; Treppiedi D; Catalano R; Ferrante E; Sala E; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Cancer Lett; 2018 Oct; 435():101-109. PubMed ID: 30098401
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
13. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
14. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
15. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
17. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
18. Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization.
Treppiedi D; Jobin ML; Peverelli E; Giardino E; Sungkaworn T; Zabel U; Arosio M; Spada A; Mantovani G; Calebiro D
Endocrinology; 2018 Aug; 159(8):2953-2965. PubMed ID: 29931263
[TBL] [Abstract][Full Text] [Related]
19. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
20. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]